---
title: "Etelcalcetide"
canonical_url: https://peptidelibrary.app/library/etelcalcetide
description: "Peptide calcimimetic approved for secondary hyperparathyroidism in adults with chronic kidney disease on haemodialysis. It is given intravenously at the end of dialysis rather than orally."
updated: 2026-11-07
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# Etelcalcetide

Etelcalcetide is an FDA-approved calcium-sensing receptor agonist. Etelcalcetide is a synthetic D-amino-acid peptide that binds the calcium-sensing receptor on parathyroid chief cells at a site distinct from the calcium binding site, forming a disulfide bond with a cysteine residue on the receptor.

Peptide calcimimetic approved for secondary hyperparathyroidism in adults with chronic kidney disease on haemodialysis. It is given intravenously at the end of dialysis rather than orally.

## Classification

- Type: FDA-approved calcium-sensing receptor agonist
- Mechanism class: Calcium-Sensing Receptor Agonist
- Development stage: Approved product
- Regulatory class: FDA-approved medicine

## Mechanism

Etelcalcetide is a synthetic D-amino-acid peptide that binds the calcium-sensing receptor on parathyroid chief cells at a site distinct from the calcium binding site, forming a disulfide bond with a cysteine residue on the receptor. This allosteric activation increases receptor sensitivity to extracellular calcium, suppressing parathyroid hormone secretion and lowering serum calcium and phosphate.

## Properties

- Molecular formula: C38H73N21O10S2
- Molecular weight: 1,048.3 g/mol
- CAS number: 1262780-97-1
- Studied routes: Intravenous

## Evidence

- Evidence level: FDA Approved
- Highest documented: Regulatory review (FDA label)
- Human trials: 0
- Controlled human trials: 0
- Preclinical sources: 0

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

### Studies

1. PARSABIV (etelcalcetide) injection — FDA prescribing information, DailyMed. Regulatory label (FDA), human. Population: Adults with chronic kidney disease on hemodialysis with secondary hyperparathyroidism. PTH within target with normal serum calcium [Source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cd270093-c6a8-4596-a4ab-e6aa0a2c8a0c)

## Safety

Human safety basis: FDA prescribing information

## Regulatory status

Etelcalcetide is an FDA-approved product for specific labelled indications. Approval does not extend to the research contexts described on this page, and approved products are prescription medicines.

- FDA status: Approved
- Availability: Prescription-Only

## Frequently asked questions

### What is Etelcalcetide?

Peptide calcimimetic approved for secondary hyperparathyroidism in adults with chronic kidney disease on haemodialysis. It is given intravenously at the end of dialysis rather than orally.

### How does Etelcalcetide work?

Etelcalcetide is a synthetic D-amino-acid peptide that binds the calcium-sensing receptor on parathyroid chief cells at a site distinct from the calcium binding site, forming a disulfide bond with a cysteine residue on the receptor. This allosteric activation increases receptor sensitivity to extracellular calcium, suppressing parathyroid hormone secretion and lowering serum calcium and phosphate.

### Is Etelcalcetide FDA approved?

Yes. Etelcalcetide is approved by the FDA, and approved products are prescription medicines. Approval is always for specific indications studied in clinical trials, so an approved status does not mean the compound is approved for every use it is discussed for. Research-chemical material sold under the same name is not the approved product.

### What peptides are similar to Etelcalcetide?

Compounds most often compared with Etelcalcetide include Angiotensin II, Cetrorelix, Corticorelin and Cosyntropin. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

## References

- [Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial — JAMA, 2017](https://pubmed.ncbi.nlm.nih.gov/28097356/)
- [Effects of active vitamin D analogs and calcimimetic agents on PTH and bone mineral biomarkers in hemodialysis patients with SHPT: a network meta-analysis — Eur J Clin Pharmacol, 2024](https://pubmed.ncbi.nlm.nih.gov/39002024/)
- [Calcimimetics treatment strategy for serum calcium and phosphate management in patients with secondary hyperparathyroidism undergoing dialysis: A systematic review and meta-analysis of randomized studies — Ther Apher Dial, 2024](https://pubmed.ncbi.nlm.nih.gov/38499495/)
- [Impact of Cinacalcet and Etelcalcetide on Bone Mineral and Cardiovascular Disease in Dialysis Patients — Curr Osteoporos Rep, 2023](https://pubmed.ncbi.nlm.nih.gov/36848027/)
- [Lessons from effect of etelcalcetide on left ventricular hypertrophy in patients with end-stage kidney disease — Curr Opin Nephrol Hypertens, 2022](https://pubmed.ncbi.nlm.nih.gov/35703173/)